0.057  0.002 (2.7%)		12-29 15:49
Open: 0.0555 High: 0.057 Volume: 755,858		Pre. Close: 0.0555 Low: 0.055 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.02	1-year :	0.03
Resists	First :	0.02	Second :	0.02
Pivot price	0.02
Supports	First :	0.01	Second :	0.01
MAs	MA(5) :	0.01	MA(20) :	0.02
	MA(100) :	0.1	MA(250) :	0.4
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	28.9	D(3) :	25.2
RSI	RSI(14): 33.2
52-week	High :	1.57	Low :	0.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ RUBY ] has closed above bottom band by 6.4%. Bollinger Bands are 93.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 38 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.02 - 0.02	0.02 - 0.02
Low:	0.02 - 0.02	0.02 - 0.02
Close:	0.02 - 0.02	0.02 - 0.02

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Wed, 22 Feb 2023
Once high-flying Rubius to shut down. Its flameout is a lesson for biotech - statnews.com

Thu, 17 Nov 2022
Former Rubius CEO jumps to another Flagship spinout - The Business Journals

Mon, 07 Nov 2022
Softbank-backed Flagship startup lays off 65, replaces CEO - The Business Journals

Fri, 23 Sep 2022
Rubius Therapeutics (RUBY) Stock Rallied 36% Despite No News - AskTraders.com

Mon, 19 Sep 2022
Flagship-backed Vesalius lays off 43% - The Business Journals

Tue, 13 Sep 2022
Rubius Therapeutics Announces Strategic Update - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	90 (M)
Shares Float	47 (M)
Held by Insiders	5.5 (%)
Held by Institutions	53.6 (%)
Shares Short	1,530 (K)
Shares Short P.Month	2,480 (K)

EPS	-2.08
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.17
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-46.7 %
Return on Equity (ttm)	-185.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.34
Qtrly Earnings Growth	0 %
Operating Cash Flow	-150 (M)
Levered Free Cash Flow	-85 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0.1
Price to Sales	0
Price to Cash Flow	-0.02

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.